Australia markets closed

Adaptive Biotechnologies Corporation (1HM.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.7050+0.1390 (+5.42%)
At close: 08:06AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 413.42M
Enterprise value 182.63M
Trailing P/E 43.06
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.33
Price/book (mrq)1.31
Enterprise value/revenue 1.07
Enterprise value/EBITDA -0.96

Trading information

Stock price history

Beta (5Y monthly) 1.24
52-week change 3-52.51%
S&P500 52-week change 322.38%
52-week high 38.4100
52-week low 32.1480
50-day moving average 32.9116
200-day moving average 34.1898

Share statistics

Avg vol (3-month) 3135
Avg vol (10-day) 3N/A
Shares outstanding 5147.37M
Implied shares outstanding 6152.83M
Float 898.38M
% held by insiders 12.79%
% held by institutions 194.41%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -132.28%
Operating margin (ttm)-99.68%

Management effectiveness

Return on assets (ttm)-16.60%
Return on equity (ttm)-58.34%

Income statement

Revenue (ttm)170.28M
Revenue per share (ttm)1.18
Quarterly revenue growth (yoy)-17.10%
Gross profit (ttm)N/A
EBITDA -179.38M
Net income avi to common (ttm)-225.25M
Diluted EPS (ttm)-1.5300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)346.4M
Total cash per share (mrq)2.39
Total debt (mrq)229.43M
Total debt/equity (mrq)74.42%
Current ratio (mrq)4.66
Book value per share (mrq)2.13

Cash flow statement

Operating cash flow (ttm)-156.32M
Levered free cash flow (ttm)-81.95M